We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Immuno-oncology
Poster
Real world experience of Pembrolizumab in advanced Head and Neck SCC during the COVID-19 pandemic
Dylan Pritchard, United Kingdom
PO-0140
Results of Concurrent SBRT and Immunotherapy in Recurrent and Metastatic Head and Neck Cancer
Melek Tugce Yilmaz, Turkey
PO-0141
Efficacy of nivolumab in rmHNSCC. A national prospective DAHANCA cohort study
Jesper Grau Eriksen, Denmark
PO-0142
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in head and neck tumours
Zsuzsanna Szilasi, Hungary
PO-0143
A phase 2 study of serplulimab plus HLX07 in patients with advanced head and neck tumours
Ye Guo, China
PO-0144
NLR and SUVmax of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation
Jonas Werner, Switzerland
PO-0145
Predictors of outcome beyond PD-L1-expression for recurrent or metastatic head and neck cancer
Bálint Tamaskovics, Hungary
PO-0146
Variation of T cells activation and PD-1 expression in sentinel node in oral SCC
Krzysztof Piersiala, Sweden
PO-0147
The immune landscape of HPV+ and HPV- head and neck cancers: a comparison of immune infiltration
Géraldine Descamps, Belgium
PO-0148
Immunoscore combining CD8, FoxP3 and CD68 expression and distribution predicts the prognosis of HNC
Géraldine Descamps, Belgium
PO-0149
Durvalumab with cetuximab and radiotherapy for locally advanced HNSCC: a phase 1/2 trial
Pierluigi Bonomo, Italy
PO-0150
Prognostic significance of immune inflammation biomarkers in 615 patients of oropharyngeal cancer
Sheetal Kashid, India
PO-0151
M2 as a therapeutic target in HNSCC: differentiation from THP-1 to M1 and M2a macrophage phenotypes
Géraldine Descamps, Belgium
PO-0152
Establishment of 3D co-culture model of head and neck squamous cell carcinomas and monocytes cells
Géraldine Descamps, Belgium
PO-0153